Testing Data
(Omalizumab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Omaliizumab Antibody (clone AbD20669, HCA236) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of omalizumab (therapeutic reference product) or Human Anti-IgE Antibody, MCA6105 (omalizumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Omalizumab Antibody (clone AbD20669_hIgG1, HCA235P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Human anti-Human IgE Monoclonal Antibody | anti-IgE antibody
Human Anti IgE (Omalizumab Biosimilar)
Reactivity
Human
Applications
ELISA
Purity
>98% by SDS PAGEPurified IgG prepared by affinity chromatography on Protein A
Synonyms
IgE; Monoclonal Antibody; Human Anti IgE (Omalizumab Biosimilar); IgE antibody (huMaE11); anti-IgE antibody
Host
Human
Reactivity
Human
Clonality
Monoclonal
Isotype
IgG1
Clone Number
huMaE11
Purity/Purification
>98% by SDS PAGE
Purified IgG prepared by affinity chromatography on Protein A
Purified IgG prepared by affinity chromatography on Protein A
Form/Format
Liquid; Phosphate Buffered Saline
Concentration
1.0 mg/ml (varies by lot)
Sequence Length
569
Applicable Applications for anti-IgE antibody
ELISA (EIA)
Immunogen
Human IgE protein
Preservative Stabilizers
0.02% Proclin 300
Preparation and Storage
Store at 4 degree C or at -20 degree C if preferred.
Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Should this product contain a precipitate we recommend microcentrifugation before use.
Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Should this product contain a precipitate we recommend microcentrifugation before use.
Testing Data
(Omalizumab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Omaliizumab Antibody (clone AbD20669, HCA236) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of omalizumab (therapeutic reference product) or Human Anti-IgE Antibody, MCA6105 (omalizumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Omalizumab Antibody (clone AbD20669_hIgG1, HCA235P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Testing Data
(Omalizumab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Omaliizumab Antibody (clone AbD20669, HCA236) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of omalizumab (therapeutic reference product) or Human Anti-IgE Antibody, MCA6105 (omalizumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Omalizumab Antibody (clone AbD20669_hIgG1, HCA235P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Testing Data
(Purity assesment by SDS-PAGE0.5 mug of Human Anti-IgE Antibody, MCA6105 (omalizumab biosimilar, research grade) and omalizumab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Purity assesment by SDS-PAGE0.5 mug of Human Anti-IgE Antibody, MCA6105 (omalizumab biosimilar, research grade) and omalizumab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-IgE Antibody, MCA6105 (omalizumab biosimilar, research grade) and omalizumab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-IgE Antibody, MCA6105 (omalizumab biosimilar, research grade) and omalizumab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
Related Product Information for anti-IgE antibody
Description: Anti-IgE Antibody is a non-therapeutic biosimilar of the monoclonal antibody drug omalizumab (Xolair) for research use. It can be used in bioanalytical assays and for studying biological pathways affected by the drug.
Summary: Human Anti-IgE Antibody, clone huMaE11 is a research grade biosimilar of the monoclonal antibody drug omalizumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic antibody omalizumab.
Human Anti-IgE Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-omalizumab antibodies, for example HCA235P and HCA236. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-omalizumab antibody in IgG1 format as reference standard, for example HCA235.
Omalizumab (Xolair) is a recombinant humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma. Allergic asthma is mediated by immunoglobulin E (IgE) released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcepsilonRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human IgE. By binding to circulating IgE at the site of FcepsilonRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release.
Summary: Human Anti-IgE Antibody, clone huMaE11 is a research grade biosimilar of the monoclonal antibody drug omalizumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic antibody omalizumab.
Human Anti-IgE Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-omalizumab antibodies, for example HCA235P and HCA236. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-omalizumab antibody in IgG1 format as reference standard, for example HCA235.
Omalizumab (Xolair) is a recombinant humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma. Allergic asthma is mediated by immunoglobulin E (IgE) released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcepsilonRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human IgE. By binding to circulating IgE at the site of FcepsilonRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release.
NCBI and Uniprot Product Information
NCBI GI #
NCBI Official Full Name
immunoglobulin epsilon chain
Protein Family
Similar Products
Product Notes
The IgE (Catalog #AAA225706) is an Antibody produced from Human and is intended for research purposes only. The product is available for immediate purchase. The Human Anti IgE (Omalizumab Biosimilar) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's IgE can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA). Researchers should empirically determine the suitability of the IgE for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "IgE, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
